PHARMACEUTICAL 2014

ELI Lilly Co
Rank 102 of 234



RealRate

PHARMACEUTICAL 2014

ELI Lilly Co
Rank 102 of 234

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 70% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 37% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	13,104,700
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,916,600
Liabilities, Non-Current	8,691,400
Other Assets	14,168,500
Other Compr. Net Income	1,794,400
Other Expenses	5,771,400
Other Liabilities	0
Other Net Income	0
Other Revenues	23,113,100
Property and Equipment	7,975,500
Research and Development	5,531,300
Selling, General and Administrative Expense	7,125,600

Output Variable	Value in 1000 USD
Assets	35,248,700
Liabilities	17,608,000
Expenses	18,428,300
Revenues	23,113,100
Stockholders Equity	17,640,700
Net Income	4,684,800
Comprehensive Net Income	5,582,000
BaseVar	48,096,250
ECR before LimitedLiability	167%
Economic Capital Ratio	280%